The monoclonal antibody fresolimumab neutralizing TGF‐β1, 2, and 3 showed modest effects in patients in a small phase 1 clinical trial of patients with malignant melanoma or renal carcinoma.124. The gene discussed is TGFB1; the disease is melanoma.